160 related articles for article (PubMed ID: 30076159)
1. Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study.
Muhammad A; Coopmans EC; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; van der Lely AJ; Neggers SJCMM
Eur J Endocrinol; 2018 Oct; 179(5):269-277. PubMed ID: 30076159
[TBL] [Abstract][Full Text] [Related]
2. Pasireotide: a novel treatment for patients with acromegaly.
Cuevas-Ramos D; Fleseriu M
Drug Des Devel Ther; 2016; 10():227-39. PubMed ID: 26811671
[TBL] [Abstract][Full Text] [Related]
3. Pasireotide: potential treatment option for McCune-Albright-associated acromegaly.
Ilie MD; Raverot G; Brac de la Perrière A
Eur J Endocrinol; 2024 Jan; 190(1):K17-K20. PubMed ID: 38128124
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of pasireotide LAR for acromegaly: a prolonged real-world monocentric study.
Favero V; Zampetti B; Carioni EI; Dalino Ciaramella P; Grossrubatscher E; Dallabonzana D; Chiodini I; Cozzi R
Front Endocrinol (Lausanne); 2024; 15():1344728. PubMed ID: 38362280
[TBL] [Abstract][Full Text] [Related]
5. Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide.
Samson SL; Nachtigall LB; Fleseriu M; Gordon MB; Bolanowski M; Labadzhyan A; Ur E; Molitch M; Ludlam WH; Patou G; Haviv A; Biermasz N; Giustina A; Trainer PJ; Strasburger CJ; Kennedy L; Melmed S
J Clin Endocrinol Metab; 2020 Oct; 105(10):e3785-97. PubMed ID: 32882036
[TBL] [Abstract][Full Text] [Related]
6. Cost-Utility of Acromegaly Pharmacological Treatments in a French Context.
Brue T; Chanson P; Rodien P; Delemer B; Drui D; Marié L; Juban L; Salvi L; Henocque R; Raverot G
Front Endocrinol (Lausanne); 2021; 12():745843. PubMed ID: 34690933
[TBL] [Abstract][Full Text] [Related]
7. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs.
Araujo-Castro M; Biagetti B; Menéndez Torre E; Novoa-Testa I; Cordido F; Pascual-Corrales E; Rodríguez Berrocal V; Guerrero-Pérez F; Vicente A; Percovich Hualpa JC; García-Centeno R; González-Fernández L; Ollero García MD; Irigaray Echarri A; Moure Rodríguez MD; Novo-Rodríguez C; Calatayud M; Villar-Taibo R; Bernabéu I; Alvarez-Escola C; Benítez Valderrama P; Tenorio-Jiménez C; Abellán Galiana P; Venegas E; González-Molero I; Iglesias P; Blanco-Carrera C; Vidal-Ostos De Lara F; de Miguel Novoa P; López Mezquita E; Hanzu FA; Aldecoa I; Aznar S; Lamas C; Aulinas A; Asla Q; Gracia Gimeno P; Recio-Córdova JM; Avilés-Pérez MD; Asensio-Wandosell D; Sampedro-Núñez M; Cámara R; Paja Fano M; Ruz-Caracuel I; Fajardo C; Marazuela M; Puig-Domingo M
Endocr Relat Cancer; 2024 Jul; 31(7):. PubMed ID: 38713182
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study.
Fleseriu M; Rusch E; Geer EB;
Endocrine; 2017 Jan; 55(1):247-255. PubMed ID: 27896545
[TBL] [Abstract][Full Text] [Related]
9. Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly.
Silverstein JM
Pituitary; 2016 Oct; 19(5):536-43. PubMed ID: 27405306
[TBL] [Abstract][Full Text] [Related]
10. Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs.
Corica G; Pirchio R; Milioto A; Nista F; Arecco A; Mattioli L; Auriemma RS; Cocchiara F; Pivonello R; Colao A; Ferone D; Gatto F
J Endocrinol Invest; 2024 Mar; 47(3):683-697. PubMed ID: 37695461
[TBL] [Abstract][Full Text] [Related]
11. Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR.
Wolf P; Dormoy A; Maione L; Salenave S; Young J; Kamenický P; Chanson P
Endocr Connect; 2022 Dec; 11(12):. PubMed ID: 36269605
[TBL] [Abstract][Full Text] [Related]
12. Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience.
Gadelha M; Marques NV; Fialho C; Scaf C; Lamback E; Antunes X; Santos E; Magalhães J; Wildemberg LE
J Clin Endocrinol Metab; 2023 Nov; 108(12):e1571-e1579. PubMed ID: 37357993
[TBL] [Abstract][Full Text] [Related]
13. Bone health and skeletal fragility in second- and third-line medical therapies for acromegaly: preliminary results from a pilot single center experience.
Chiloiro S; Giampietro A; Infante A; Mattogno PP; Lauretti L; Olivi A; De Marinis L; Pontecorvi A; Doglietto F; Bianchi A
Pituitary; 2024 Jun; 27(3):303-309. PubMed ID: 38713317
[TBL] [Abstract][Full Text] [Related]
14. Real-life data of Pasireotide LAR in acromegaly: a long-term follow-up.
Urbani C; Dassie F; Zampetti B; Mioni R; Maffei P; Cozzi R; Bogazzi F
J Endocrinol Invest; 2024 Jan; ():. PubMed ID: 38244140
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment:
Feldt-Rasmussen U; Bolanowski M; Zhang SL; Yu Y; Witek P; Kalra P; Kietsiriroje N; Piacentini A; Pedroncelli AM; Samson SL
Front Endocrinol (Lausanne); 2024; 15():1250822. PubMed ID: 38577574
[TBL] [Abstract][Full Text] [Related]
16. MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly.
Fleseriu M; Molitch M; Dreval A; Pokramovich Y; Bondar I; Poteshkin Y; Macut D; Obermayer-Pietsch B; Gilgun-Sherki Y; Haviv A; Biermasz N; Strasburger CJ
J Clin Endocrinol Metab; 2023 Nov; 108(12):3214-3222. PubMed ID: 37319438
[TBL] [Abstract][Full Text] [Related]
17. Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts' consensus statement.
Störmann S; Meyhöfer SM; Groener JB; Faust J; Schilbach K; Seufert J; Vergès B
Front Endocrinol (Lausanne); 2024; 15():1348990. PubMed ID: 38405148
[TBL] [Abstract][Full Text] [Related]
18. Successful medical management of a pituitary macroadenoma with features of resistant acromegaly and hyperprolactinemia using pasireotide.
Baagar KA; Sadiq A; Khan AA; Dabbous Z; Rohani Z
Qatar Med J; 2024; 2024(1):17. PubMed ID: 38654814
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Pegvisomant in the Treatment of Acromegaly.
Haberbosch L; Strasburger CJ
Arch Med Res; 2023 Dec; 54(8):102884. PubMed ID: 37659952
[TBL] [Abstract][Full Text] [Related]
20. Nanomedicines in the treatment of acromegaly: focus on pegvisomant.
Roelfsema F; Biermasz NR; Pereira AM; Romijn J
Int J Nanomedicine; 2006; 1(4):385-98. PubMed ID: 17722273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
